The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Atypical progeroid syndrome
LMNA-C588R
LMNA-D325N
LMNA-E138K
LMNA-M540T
LMNA-R644C
ZMPSTE24-L425P
ZMPSTE24-P248L
mandibuloacral dysplasia-type B
prelamin A
Journal
Nucleus (Austin, Tex.)
ISSN: 1949-1042
Titre abrégé: Nucleus
Pays: United States
ID NLM: 101518322
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
7
12
2023
pubmed:
5
12
2023
entrez:
5
12
2023
Statut:
ppublish
Résumé
Several related progeroid disorders are caused by defective post-translational processing of prelamin A, the precursor of the nuclear scaffold protein lamin A, encoded by
Identifiants
pubmed: 38050983
doi: 10.1080/19491034.2023.2288476
doi:
Substances chimiques
lonafarnib
IOW153004F
Lamin Type A
0
Enzyme Inhibitors
0
Transferases
EC 2.-
Metalloendopeptidases
EC 3.4.24.-
ZMPSTE24 protein, human
EC 3.4.24.84
Membrane Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM